Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(10): 642-648
DOI: 10.1055/s-0043-112861
Article
© Georg Thieme Verlag KG Stuttgart · New York

Pregnancy and Tumor Outcomes in Women with Prolactinoma

Prolactinoma and Pregnancy: Outcomes
Bárbara Araujo
1   Faculty of Medicine, University of Porto. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
,
Sandra Belo
1   Faculty of Medicine, University of Porto. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
2   Department of Endocrinology, Diabetes and Metabolism Centro Hospitalar S. João. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
3   I3s – Instituto de Investigação e Inovação em Saúde, Universidade do Porto. R. Alfredo Allen, 4200-135 Porto, Portugal
,
Davide Carvalho
1   Faculty of Medicine, University of Porto. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
2   Department of Endocrinology, Diabetes and Metabolism Centro Hospitalar S. João. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
3   I3s – Instituto de Investigação e Inovação em Saúde, Universidade do Porto. R. Alfredo Allen, 4200-135 Porto, Portugal
› Author Affiliations
Further Information

Publication History

received 17 March 2017
revised 15 May 2017

accepted 01 June 2017

Publication Date:
13 July 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Context Management of prolactinomas during pregnancy has always been a challenge. There is a concern about the risk of tumor growth, as well as the effects of the treatment on the developing fetus. Another issue that has been less studied is the outcome of women with prolactinoma after pregnancy and lactation.

Objectives To evaluate remission of hyperprolactinaemia after pregnancy and lactation in women with prolactinoma. To describe the safety of dopamine agonists for the fetus and pregnancy outcomes.

Methods A retrospective study of 32 pregnancies in women with prolactinoma was conducted in a single-centre. Other causes of hyperprolactinemia were excluded. Prolactin level was recorded at the time of diagnosis, during treatment, and during follow-up.

Results The pregnancies resulted in one spontaneous abortion (3.1%) and 31 live births (96.9%). No stillbirths, multiple or ectopic pregnancies or trophoblastic disease were recorded. There was only one malformation (club foot) recorded (3.1%) and normalisation of prolactin after pregnancy without medical treatment occurred in 12% of patients.

Conclusions Fetal exposure to bromocriptine or cabergoline during pregnancy is not associated with an increased risk of adverse neonatal or pregnancy disclosures. There is considerable diversity among endocrinologists in the management of prolactinomas during pregnancy and after birth, which indicates that there is a need for better consensus and for carefully drawn-up guidelines to follow.

Key words

prolactin - pituitary tumor - hyperprolactinemia - dopamine agonists
 

  • References

  • 1 Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8: 3-6
    Google Scholar
  • 2 Daly AF, Rixhon M, Adam C. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775
    CrossrefPubMedGoogle Scholar
  • 3 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
    CrossrefPubMedGoogle Scholar
  • 4 Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 2015; 172: R205-R213
    CrossrefPubMedGoogle Scholar
  • 5 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
    CrossrefPubMedGoogle Scholar
  • 6 Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine 2014; 47: 64-69
    CrossrefPubMedGoogle Scholar
  • 7 Domingue ME, Devuyst F, Alexopoulou O. et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 2014; 80: 642-648
    CrossrefPubMedGoogle Scholar
  • 8 Rjosk HK, Fahlbusch R, von Werder K. Influence of pregnancies on prolactinomas. Acta endocrinologica 1982; 100: 337-346
    PubMedGoogle Scholar
  • 9 Crosignani PG, Mattei AM, Severini V. et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 1992; 44: 175-180
    CrossrefPubMedGoogle Scholar
  • 10 Jeffcoate WJ, Pound N, Sturrock ND. et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996; 45: 299-303
    CrossrefPubMedGoogle Scholar
  • 11 Raymond JP, Goldstein E, Konopka P. et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res 1985; 22: 239-246
    CrossrefPubMedGoogle Scholar
  • 12 Randeva HS, Davis M, Prelevic GM. Prolactinoma and pregnancy. Br J Obstet Gynaecol 2000; 107: 1064-1068
    CrossrefPubMedGoogle Scholar
  • 13 Bronstein MD. Prolactinomas and pregnancy. Pituitary 2005; 8: 31-38
    CrossrefPubMedGoogle Scholar
  • 14 Molitch ME. Pituitary tumors and pregnancy. Growth Horm IGF Res 2003; 13: S38-S44
    CrossrefPubMedGoogle Scholar
  • 15 Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25: 885-896
    CrossrefPubMedGoogle Scholar
  • 16 Hamilton BE, Martin JA, Osterman MJ. et al. Final Data for 2014. Natl Vital Stat Rep 2015; 64: 1-64
    PubMedGoogle Scholar
  • 17 Auriemma RS, Perone Y, Di Sarno A. et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013; 98: 372-379
    CrossrefPubMedGoogle Scholar
  • 18 Casanueva FF, Molitch ME, Schlechte JA. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265-273
    CrossrefPubMedGoogle Scholar
  • 19 Ikegami H, Aono T, Koizumi K. et al. Relationship between the methods of treatment for prolactinomas and the puerperal lactation. Fertil Steril 1987; 47: 867-869
    CrossrefPubMedGoogle Scholar
  • 20 Colao A, Abs R, Barcena DG. et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008; 68: 66-71
    CrossrefPubMedGoogle Scholar
  • 21 Ricci E, Parazzini F, Motta T. et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791-793
    CrossrefPubMedGoogle Scholar
  • 22 Robert E, Musatti L, Piscitelli G. et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-337
    CrossrefPubMedGoogle Scholar
  • 23 Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823-827
    CrossrefPubMedGoogle Scholar
  • 24 Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry 2001; 71: 542-545
    CrossrefPubMedGoogle Scholar
  • 25 Witek P, Zielinski G, Maksymowicz M. et al. Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy. Neuro Endocrinol Lett 2012; 33: 483-488
    PubMedGoogle Scholar
  • 26 Rajasekaran S, Vanderpump M, Baldeweg S. et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74: 9-20
    CrossrefPubMedGoogle Scholar
  • 27 Brodsky JB, Cohen EN, Brown Jr BW. et al. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980; 138: 1165-1167
    CrossrefPubMedGoogle Scholar
  • 28 Tyson JE, Hwang P, Guyda H. et al. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113: 14-20
    CrossrefPubMedGoogle Scholar
  • 29 Serri O, Chik CL, Ur E. et al. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575-581
    PubMedGoogle Scholar
  • 30 Almalki MH, Ur E, Johnson M. et al. Management of prolactinomas during pregnancy – a survey of four Canadian provinces. Clin Invest Med 2012; 35: E96-104
    PubMedGoogle Scholar
  • 31 Beshyah SA, Sherif IH, Chentli F. et al. Management of prolactinomas: a survey of physicians from the Middle East and North Africa. Pituitary 2016; 1-10
    PubMedGoogle Scholar
  • 32 Vilar L, Naves LA, Casulari LA. et al. Management of prolactinomas in Brazil: an electronic survey. Pituitary 2010; 13: 199-206
    CrossrefPubMedGoogle Scholar